A Study to Evaluate the Safety and Pharmacokinetics of HH-120 Nasal Spray in Healthy Volunteers

NCT05753878 | Completed Phase 1

• 1 other identifier: HH120-NS111
• Study Type: interventional
• Target: 62
• Locations: 1 country
• Sites: 1

Brief Summary

This is a clinical study evaluating the safety, tolerability, pharmacokinetic (PK) characteristics and immunogenicity of HH-120 nasal spray in healthy subjects. This study is divided into two parts: Part A is of open-label design and mainly aims to assess the local distribution and PK in nasal cavity of HH-120 nasal spray, subjects from 10 cohorts are sequentially enrolled to perform either nasal endoscopic examination or nasal/ nasopharyngeal samples collection at different time points post administration. Part B mainly aims to assess the safety, systematic pharmacokinetic and immunogenicity after multiple dosing of HH-120 nasal spray, subjects are randomly assigned (3:1) to HH-120 and placebo groups.

Conditions

COVID-19

Outcome Measures

Primary Outcomes (3)

• The distribution of HH-120 in the nasal cavity at different time points after single dose of HH-120 nasal spray.(Part A: cohort 1)

  From baseline to the end of the 7-day follow-up.

• Local drug concentration of nasal and nasopharyngeal swab samples before and at different time points after dosing of HH-120 nasal spray.(Part A: cohort 2-9)

  From baseline to the end of the 7-day follow-up.

• The incidence and severity of adverse events and the serious adverse events.(Part B)

  From baseline to the end of the 29-day follow-up.

Secondary Outcomes (5)

• The incidence and severity of adverse events and the serious adverse events.(Part A)

  From baseline to the end of the 7-day follow-up.

• Drug concentration of nasopharyngeal swab samples before and after multiple dosing of HH-120 nasal spray.(Part B)

  From baseline to the end of the 29-day follow-up.

• Maximum plasma concentration (Cmax).(Part B)

  From baseline to the end of the 29-day follow-up.

• Peak time (Tmax).(Part B)

  From baseline to the end of the 29-day follow-up.

• The incidence and titer of anti-drug antibody (ADA).(Part B)

  From baseline to the end of the 29-day follow-up.

Other Outcomes (1)

• The in vitro SARS-CoV-2 neutralization activity of nasal and nasopharyngeal swab samples at different time points after dosing.(Part A)

  From baseline to the end of the 7 days follow-up.

Study Arms (5)

HH-120 nasal spray, Part A cohort 1

EXPERIMENTAL

Nasal endoscopic examination is performed at 3min (±2 min), 30min (±5 min), 1h (±10 min), and 2h (±10 min) after dosing.

Drug: HH-120 nasal spray, PartA cohort 1

HH-120 nasal spray, Part A cohort 2-7

EXPERIMENTAL

Nasal/nasopharyngeal samples are collected at 3min (±2 min) , 1h (±10 min) ,2h (±10 min),4h (±30 min),8h (±30 min),24h (±30 min).

Drug: HH-120 nasal spray, Part A cohort 2-7

HH-120 nasal spray, Part A cohort 8-9

EXPERIMENTAL

Nasal/nasopharyngeal samples are collected at 4h (±30 min) , 8h (±30 min).

Drug: HH-120 nasal spray, Part A cohort 8-9

HH-120 nasal spray, Part B

EXPERIMENTAL

Drug: HH-120 nasal spray, Part B

Placebo nasal spray, Part B

PLACEBO COMPARATOR

Other: Placebo nasal spray, Part B

Interventions

HH-120 nasal spray, PartA cohort 1 DRUG

A single dose of HH-120 nasal spray premixed with 1mg/ml methylene blue injection.

HH-120 nasal spray, Part A cohort 1

HH-120 nasal spray, Part A cohort 2-7 DRUG

A single dose of HH-120 nasal spray.

HH-120 nasal spray, Part A cohort 2-7

HH-120 nasal spray, Part A cohort 8-9 DRUG

Two doses of HH-120 nasal spray.

HH-120 nasal spray, Part A cohort 8-9

HH-120 nasal spray, Part B DRUG

HH-120 nasal spray, 10 times daily for 7 consecutive days.

HH-120 nasal spray, Part B

Placebo nasal spray, Part B OTHER

Placebo nasal spray, 10 times daily for 7 consecutive days.

Placebo nasal spray, Part B

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and female subjects aged 18 to 65 (including 18 and 65 years old);
• The weight of male subjects is not less than 50 kg, and the weight of female subjects is not less than 45 kg. Body Mass Index (BMI) = weight (kg)/height2 (m2), BMI is within the range of 18\~28kg/m2 (including the critical value);
• Normal physical examination, vital signs, laboratory tests and other auxiliary examinations (chest imaging, abdominal B-ultrasound, electrocardiogram, etc.) or abnormality without clinical significance.
• Willing and able to give written informed consent.

You may not qualify if:

• Participated in any other clinical research with drug intervention within 4 weeks before screening, or the drug is still in the elimination period (5 half-lives) before screening, whichever is longer;
• Have used therapeutic biological agents within 12 weeks before screening, or are within the drug elimination period (5 half-lives) at the time of random administration, whichever is longer;
• Have been vaccinated within 12 weeks before screening, or plan to receive BCG or other vaccines during the study or within 12 weeks after the study;
• Have used any prescription drugs, non-prescription Chinese herbal medicines or health products within 14 days (inclusive) before the screening;
• Have undergone any major surgery within 8 weeks (including 8 weeks) before screening, or need to undergo such surgery during the study period, and deemed by the investigator and the sponsor that such surgery may bring unacceptable risk to the subject.;Physical examination, laboratory abnormalities, and medical history;
• Supine systolic blood pressure (SBP) \>140mmHg or \<90 mmHg, and/or diastolic blood pressure (DBP) \>90mmHg or \<50 mmHg during the screening period;
• Supine 12-lead electrocardiogram showing QTcF interval \> 450 ms (male) or \> 470 ms (female). and/or other abnormalities with clinical significance during screening;
• History of systemic or respiratory infection within 2 weeks before screening, or concurrent viral or bacterial infection (fever or other symptoms) during screening;
• Have received vital organ transplantation (such as heart, lung, liver, kidney, etc.);
• Have malignant tumor diseases (excluding malignant tumors that have been cured and have no recurrence within the past 5 years, completely resected basal cell and squamous cell skin cancers, and completely resected carcinoma in situ of any type);
• Hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (Anti-HCV), Treponema pallidum antibody and acquired immunodeficiency syndrome (HIV) antibody positive;
• History of cardiovascular system, digestive system, kidney, liver, endocrine system, blood and lymphatic system, immune, nervous system or mental disorders or any other significant diseases, or suffer from chronic rhinitis or allergic rhinitis, drug abuse, alcoholism
• Have a history of drug abuse or used drugs in the past six months or have a positive urine drug screening;
• Have a history of alcoholism or excessive alcohol intake in the past 6 months (drinking 14 units of alcohol per week: 1 unit = 285mL of beer, or 25mL of spirits, or 100mL of wine), or those who have a positive alcohol breath test; or test Cannot cooperate with non-drinkers during the period;
• Known hypersensitivity to any ingredient used in the dosage form of intervention therapy; ever hypersensitivity (regardless of degree) to other monoclonal antibody drugs and therapeutic protein preparations (fresh or frozen plasma, human serum albumin, cytokines, interleukins, etc.) ; or have a clear past allergy to inhalant allergens (regardless of degree);

Sponsors & Collaborators

• Huahui Health: lead

Study Sites (1)

Beijing TongRen Hospital, Capital Medical University

Beijing, Beijing Municipality, 100730, China

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 23, 2023
• First Posted: March 3, 2023
• Study Start: November 8, 2022
• Primary Completion: January 9, 2023
• Study Completion: January 9, 2023
• Last Updated: September 28, 2023

Record last verified: 2023-09

Locations

CN (1)